日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium

早期复发时间作为淋巴结成熟T细胞淋巴瘤生存预后指标:来自PETAL联盟的研究结果

Sorial, Mark N; Malpica Castillo, Luis E; Chiattone, Carlos; Julia, Edith; Bachy, Emmanuel; Barta, Stefan K; Stuver, Robert; Jacobsen, Eric; Federico, Massimo; Jain, Hasmukh; Prince, H Miles; Foss, Francine; Zinzani, Pier Luigi; Okatani, Takeshi; Kim, Won-Seog; Verburgh, Estelle; Al-Mansour, Mubarak; Cabrera, Maria Elena; Bhagat, Govind; Shen, Changyu; Jain, Salvia

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up

更正:Brentuximab vedotin联合化疗一线治疗系统性间变性大细胞淋巴瘤:ECHELON-2研究5年随访亚组分析

Domingo-Domènech, Eva; Pro, Barbara; Illidge, Tim; Horwitz, Steven; Trumper, Lorenz; Iyer, Swami; Advani, Ranjana; Bartlett, Nancy L; Christensen, Jacob Haaber; Kim, Won-Seog; Feldman, Tatyana; Choi, Ilseung; Gritti, Giuseppe; Belada, David; Shustov, Andrei; Illes, Arpad; Zinzani, Pier Luigi; Hüttmann, Andreas; Trneny, Marek; Le Gouill, Steven; Jagadeesh, Deepa; Friedberg, Jonathan W; Little, Meredith; Dong, Cassie; Fanale, Michelle; Fenton, Keenan; Savage, Kerry J

ORY1001 enhances anti-tumor immunity via CXCL10-mediated macrophage modulation in EBV-positive DLBCL.

ORY1001 通过 CXCL10 介导的巨噬细胞调节增强 EBV 阳性 DLBCL 的抗肿瘤免疫力。

Kim Joo Hyun, Cho Hyeon Ji, Yoon Sang Eun, Kim Won Seog

Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed/refractory diffuse large B-cell lymphoma

复发/难治性弥漫性大B细胞淋巴瘤CAR-T细胞疗法疗效的微生物组和代谢物生物标志物

Yoon, Sang Eun; Kang, Woorim; Cho, Junhun; Cho, Hyeon Ji; Chalita, Mauricio; Oh, Hyun-Seok; Hyun, Dong-Wook; Han, Sujeong; Kim, Hyun; Sung, Hojun; Lee, Jae-Yun; Park, Bon; Ryu, Kyung Ju; Kim, Hyun-Young; Cho, Duck; Kim, Won Seog; Kim, Seok Jin

Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial

epcoritamab治疗复发或难治性大B细胞淋巴瘤的疗效和安全性:EPCORE NHL-1试验的3年更新结果

Karimi, Yasmin H; Cheah, Chan Y; Clausen, Michael Roost; Cunningham, David; Farooq, Umar; Feldman, Tatyana; Ghesquieres, Herve; Jurczak, Wojciech; Linton, Kim M; Phillips, Tycel; Vose, Julie M; Kim, Won Seog; Jafarinasabian, Pegah; D'Angelo Månsson, Barbara; Soong, David; Steele, Andrew J; Li, Zhu; Eskelund, Christian W; Hutchings, Martin; Thieblemont, Catherine

Real-world use of polatuzumab vedotin combined with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma

在复发或难治性大B细胞淋巴瘤患者中,polatuzumab vedotin联合苯达莫司汀和利妥昔单抗的真实世界应用

Kim, Changgon; Yoon, Sang Eun; Kim, Hyun-Young; Cho, Duck; Cho, Junhun; Kim, Won Seog; Kim, Seok Jin

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

大型临床试验中患者报告结局(PRO)与临床医生报告的不良事件:POLARIX 3期研究结果

Thompson, Carrie; Trněný, Marek; Morschhauser, Franck; Salles, Gilles; Reagan, Patrick M; Hertzberg, Mark; Zhang, Huilai; Thieblemont, Catherine; Hu, Bei; Fonseca, Gustavo; Kim, Won Seog; Martelli, Maurizio; Mehta, Amitkumar; Singh, Avrita; Yan, Mark; Hirata, Jamie; Sugidono, Matthew; Lee, Calvin; Sharman, Jeff P; Mehta-Shah, Neha; Flowers, Christopher R; Tilly, Hervé; Chua, Neil; Casasnovas, René-Olivier; Miall, Fiona; Kim, Tae Min; Tsai, Xavier Cheng-Hong; Nasta, Sunita; Lee, Seung Tae; Friedberg, Jonathan W

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

莫苏妥珠单抗联合波拉妥珠单抗治疗不适合移植的难治性/复发性大B细胞淋巴瘤:III期SUNMO试验的主要结果

Budde, Lihua E; Zhang, Huilai; Kim, Won-Seog; Maruyama, Dai; Rego, Eduardo M; Norasetthada, Lalita; Hong, Huangming; Ozcan, Muhit; Jeon, Young-Woo; Leão Cordeiro de Farias, Danielle; Fogliatto, Laura Maria; Pavlovsky, Astrid; Goto, Hideki; Olszewski, Adam J; Shah, Nikesh; Hu, Bei; Yin, Shen; Wu, Hao; To, Iris; Ead, Wahib S; Ashby, Joan; Janousek, Martin; Pham, Song; Wang, Jue; Kwan, Antonia; Batlevi, Connie L; Wei, Michael C; Westin, Jason

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma

布伦妥昔单抗联合维多汀治疗复发性弥漫性大B细胞淋巴瘤

Bartlett, Nancy L; Hahn, Uwe; Kim, Won-Seog; Fleury, Isabelle; Laribi, Kamel; Bergua, Juan-Miguel; Bouabdallah, Krimo; Forward, Nicholas; Bijou, Fontanet; MacDonald, David; Portell, Craig A; Ghesquieres, Herve; Nowakowski, Grzegorz; Yasenchak, Christopher A; Patterson, Monica; Ho, Linda; Rustia, Evelyn; Fanale, Michelle; Jie, Fei; Kim, Jeong-A

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

作者更正:Odronextamab 单药治疗复发/难治性弥漫性大 B 细胞淋巴瘤患者:ELM-2 II 期试验的主要疗效和安全性分析

Kim, Won Seog; Kim, Tae Min; Cho, Seok-Goo; Jarque, Isidro; Iskierka-Jażdżewska, Elżbieta; Poon, Li Mei; Prince, H Miles; Zhang, Huilai; Cao, Junning; Zhang, Mingzhi; Tessoulin, Benoît; Oh, Sung Yong; Lim, Francesca; Carpio, Cecilia; Tan, Tran-Der; Ayyappan, Sabarish; Gutierrez, Antonio; Cai, Jingxian; Ufkin, Melanie; Shariff, Saleem; Brouwer-Visser, Jurriaan; Chaudhry, Aafia; Mohamed, Hesham; Ambati, Srikanth; Walewski, Jan